Search Results
10
Everything
Search Filters
Organization
Akari Therapeutics Plc
Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer
March 20, 2025 08:35 ET
|
Akari Therapeutics Plc
Former SVP and Franchise Head for US Oncology at Jazz Pharmaceuticals, with established track record for leading a portfolio of products spanning both solid and hematological malignancies that have...
Akari Therapeutics Announces $7.6 Million Private Placement Offering Led by Existing Shareholders and Insiders Priced at the Market Under Nasdaq Rules
March 03, 2025 09:00 ET
|
Akari Therapeutics Plc
BOSTON and LONDON, March 03, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (Nasdaq: AKTX), a biotechnology company developing next-generation precision bi-functional antibody drug conjugates...
Akari Therapeutics Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
February 19, 2025 09:00 ET
|
Akari Therapeutics Plc
On-demand video webcast now available here BOSTON and LONDON, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing next-generation precision...
Akari Therapeutics Joins Webull Corporate Connect Service Platform
February 03, 2025 08:00 ET
|
Akari Therapeutics Plc
Innovative targeted oncology company built on next-generation ADCs and a novel discovery engine Connect with the Company on Webull here BOSTON and LONDON, Feb. 03, 2025 (GLOBE NEWSWIRE) --...
Akari Therapeutics Announces Key Leadership Appointments
December 18, 2024 08:51 ET
|
Akari Therapeutics Plc
Samir R. Patel, M.D., appointed as Chief Executive Officer Abizer Gaslightwala appointed to Board of Directors BOSTON and LONDON, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc...
Akari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial Officer
December 16, 2024 09:05 ET
|
Akari Therapeutics Plc
BOSTON and LONDON, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) today announced the appointment of Torsten Hombeck, Ph.D. as Chief Financial Officer, effective December...
Akari Therapeutics Regains Full Nasdaq Compliance
November 19, 2024 08:00 ET
|
Akari Therapeutics Plc
- Shareholders Equity Deficiency has been Cured - - Akari will Continue to be Listed and Traded on The Nasdaq Stock Market - BOSTON and LONDON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Akari...
Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio
November 14, 2024 16:15 ET
|
Akari Therapeutics Plc
- Secures $3.2m in PIPE Financing -- $50m Term Sheet Obtained for Available Financing under Equity Line of Credit - BOSTON and LONDON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc...
Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger
November 08, 2024 08:00 ET
|
Akari Therapeutics Plc
BOSTON and LONDON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory...
Akari Therapeutics Announces Effectiveness of Form S-4 and General Meeting Date of November 7, 2024 Related to Peak Bio Merger
October 15, 2024 08:00 ET
|
Akari Therapeutics Plc
BOSTON and LONDON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory...